Exelixis, Inc. EXEL
67.65 USD -0.64 (-0.94%)
As ofNov 19, 2026, 9:38 AM EST
67.55 Day range 68.51
39.71 52-week range 73.69
- YTD
- +54.35%
- 1 year
- +60.54%
News
marketbeat.com Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO Exelixis NASDAQ: EXEL is preparing for a transition from a company built around its CABO franchise to one with multiple products, as it advances seven pivotal studies of Zanza and weighs additional…
seekingalpha.com Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript
fool.com Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything Cabometyx's sales keep growing, but generic competition looms by the end of the decade. Meanwhile, zanzalintinib could earn approval by March of 2027.benzinga.com Morgan Stanley Maintains Equal-Weight on Exelixis, Lowers Price Target to $57 Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and lowers the price target from $60 to $57.
fool.com Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch. Exelixis' cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years. The company is now betting on a next-generation candidate that's approaching the…benzinga.com Leerink Partners Maintains Market Perform on Exelixis, Raises Price Target to $58 Leerink Partners analyst Asthika Goonewardene maintains Exelixis (NASDAQ:EXEL) with a Market Perform and raises the price target from $55 to $58.
benzinga.com Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter Regeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.benzinga.com HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $78 HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $56 to $78.
benzinga.com TD Cowen Maintains Buy on Exelixis, Raises Price Target to $76 TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $55 to $76.
benzinga.com Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $60 Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $53 to $60.
benzinga.com RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $58 RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $51 to $58.
benzinga.com Truist Securities Maintains Hold on Exelixis, Raises Price Target to $60 Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $54 to $60.
benzinga.com Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $54 Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $49 to $54.
benzinga.com AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
benzinga.com Exelixis Q3 2026 Earnings Call Transcript Exelixis (NASDAQ:EXEL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…benzinga.com Exelixis Affirms FY2026 Sales Guidance of $2.500B-$2.550B vs $2.549B Est Exelixis (NASDAQ:EXEL) affirms FY2026 sales outlook from $2.500 billion-$2.550 billion to $2.500 billion-$2.550 billion vs $2.549 billion estimate.
benzinga.com Exelixis Q3 Adj. EPS $0.94 Beats $0.80 Estimate, Sales $658.696M Beat $646.510M Estimate Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.80 by 17.5 percent. This is a 20.51 percent increase over earnings of $0.78 per…
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…benzinga.com Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65 Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target from $55 to $65.
